Abbott Laboratories

AIDS researchers to Abbott: Norvir price increase cannot be tolerated

Published in AIDS Weekly and Law, May 13th, 2004

Physicians and researchers from the HIV Outpatient Study (HOPS), a diverse multicenter research collaborative, voiced their opposition to Abbott Laboratories' increase in the price of Norvir, in an open petition to Abbott CEO Miles White and Vice President John Leonard.

The HOPS investigators agreed that the Novir price increase was unprecedented, unethical and threatens access to care across the United States. In the letter, the investigators stated that Abbott's pledge to freeze the price of Novir to publicly funded drug programs failed to address the full impact of the policy, calling the Novir price increase "highly injurious to the U.S. HIV treatment and research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly and Law

Source: AIDS Weekly and Law (2004-05-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry